title: Myeloid growth factors.
abstract: Febrile neutropenia, a common side effect of myelosuppressive chemotherapy in patients with cancer, can result in prolonged hospitalization and broad-spectrum antibiotic use, often prompting treatment delays or dose reductions of drug regimens. Prophylactic use of myeloid growth factors (mainly the colony-stimulating factors filgrastim and pegfilgrastim) in patients of heightened risk can reduce the severity and duration of febrile neutropenia. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Myeloid Growth Factors provide recommendations on the use of these agents mainly in the oncology setting based on clinical evidence and expert consensus. This version includes revisions surrounding the issue of timing of pegfilgrastim administration. It also includes new sections on tbo-filgrastim, a recently approved agent that is biologically similar to filgrastim, and the role of myeloid growth factors in the hematopoietic cell transplant setting.
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Crawford
authors.forename: James
authors.initials: J
authors.lastname: Armitage
authors.forename: Lodovico
authors.initials: L
authors.lastname: Balducci
authors.forename: Pamela Sue
authors.initials: PS
authors.lastname: Becker
authors.forename: Douglas W
authors.initials: DW
authors.lastname: Blayney
authors.forename: Spero R
authors.initials: SR
authors.lastname: Cataland
authors.forename: Mark L
authors.initials: ML
authors.lastname: Heaney
authors.forename: Susan
authors.initials: S
authors.lastname: Hudock
authors.forename: Dwight D
authors.initials: DD
authors.lastname: Kloth
authors.forename: David J
authors.initials: DJ
authors.lastname: Kuter
authors.forename: Gary H
authors.initials: GH
authors.lastname: Lyman
authors.forename: Brandon
authors.initials: B
authors.lastname: McMahon
authors.forename: Hope S
authors.initials: HS
authors.lastname: Rugo
authors.forename: Ayman A
authors.initials: AA
authors.lastname: Saad
authors.forename: Lee S
authors.initials: LS
authors.lastname: Schwartzberg
authors.forename: Sepideh
authors.initials: S
authors.lastname: Shayani
authors.forename: David P
authors.initials: DP
authors.lastname: Steensma
authors.forename: Mahsa
authors.initials: M
authors.lastname: Talbott
authors.forename: Saroj
authors.initials: S
authors.lastname: Vadhan-Raj
authors.forename: Peter
authors.initials: P
authors.lastname: Westervelt
authors.forename: Michael
authors.initials: M
authors.lastname: Westmoreland
authors.forename: Mary
authors.initials: M
authors.lastname: Dwyer
authors.forename: Maria
authors.initials: M
authors.lastname: Ho
mesh_terms: D064146:Chemotherapy-Induced Febrile Neutropenia / Q000188:drug therapy* / Q000517:prevention & control; D002908:Chronic Disease; D003115:Colony-Stimulating Factors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D019650:Hematopoietic Stem Cell Mobilization; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D009503:Neutropenia / Q000188:drug therapy / Q000209:etiology; D011292:Premedication; D016896:Treatment Outcome
chemical_list: D003115:Colony-Stimulating Factors